Market News AIOpen the app

Aclaris Therapeutics shared results from its Phase 2 ADMIRATION trial, which did not meet its main goal.

TrialRead the original at SEC EDGAR
Bad for ACRS

Aclaris said its bosakitug trial missed its main and secondary goals, weakening the case for the drug. Biomarker changes and good tolerability were positives, but they did not outweigh the failed goals.

ACRS · Aclaris Therapeutics, Inc.

AI read · Bad for ACRS

The AI's read

This weakens the case for bosakitug as a treatment because the trial did not meet its measured goals. Biomarker changes and good tolerability are encouraging, but they did not show that patients improved. Aclaris has other drug trials planned, but their results are still ahead.

Get alerts for ACRS

Follow Aclaris Therapeutics, Inc. (ACRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACRS
Free on the App Store and Google Play, or on the web.